Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block

E-ISSN： 1875-6115|11|2|131-149

ISSN： 1871-5222

Source： Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Immunology, Endocrine and Metabolic Agents), Vol.11, Iss.2, 2011-06, pp. : 131-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ErbB receptor family: a therapeutic target for cancer

By de Bono J.S. Rowinsky E.K.

Trends in Molecular Medicine, Vol. 8, Iss. 4, 2002-04 ,pp. : 19-26

Elsevier

Access to resources Recommend Favorite

Structure-based approaches to inhibition of erbB receptors with peptide mimetics

By Berezov Alan Greene Mark Murali Ramachandran

Immunologic Research, Vol. 27, Iss. 2-3, 2003-06 ,pp. : 303-308

Humana Press, Inc

Access to resources Recommend Favorite

Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs

By Slovin Susan F

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1347-1355

Future Medicine

Access to resources Recommend Favorite

Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases

Current Molecular Medicine, Vol. 13, Iss. 4, 2013-05 ,pp. : 626-639

Bentham Science Publishers

Access to resources Recommend Favorite

Cooperating Oncogenic Events in Murine Mammary Tumorigenesis: Assessment of ErbB2, Mutant p53, and Mouse Mammary Tumor Virus

By Zelazny E. Li B. Anagnostopoulos A.-M. Coleman A. Perkins A.S.

Experimental and Molecular Pathology, Vol. 70, Iss. 3, 2001-06 ,pp. : 183-193

Elsevier

Access to resources Recommend Favorite